Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPCOvid-1: Convalescent Plasma for Hospitalized COVID-19 Patients
NCT04388410Phase 3Unknown
- Sponsor
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
- Start
- Aug 2020
- Primary completion
- Nov 2020
- Modality
- Biologic
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of convalescent plasma (Heinrich-Heine University, Duesseldorf) in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Primary endpoints: Severity and death at 28 days and Adverse events that require study treatment interruption at 28 days. Status: unknown.
02
Drugs
convalescent plasma (Heinrich-Heine University, Duesseldorf)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04388410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04388410.